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BACKGROUND
• Child TB accounts for 11% of the 10 million global cases
• Children shoulder a disproportionate share of TB mortality (14%)
• 96% of child TB deaths occur in the undiagnosed (Dodd et al, Lancet Global Health, 2017) 
• Previous Xpert MTB/RIF Review (Detjen et al, Lancet Resp Med, 2015)
• sensitivity (62% sputum, 66% gastric specimen) 
• specificity (98% sputum and gastric specimens)
• Updated the systematic review as additional Xpert MTB/RIF studies have been 
published and Xpert Ultra was introduced in order to inform 2020 WHO TB 
molecular diagnostic guidelines
METHODS: SEARCH
• Searched multiple databases without language 
restriction to 29 Apr 2019
• Covidence systematic review software to manage 
selection of studies
• Reviewed reference lists of articles and review articles
• Reviewed included studies from prior review
• Data obtained directly from manuscripts and through 
author inquiries
METHODS: APPROACH
• Types of Studies: Diagnostic accuracy cross-sectional studies, cohort studies, 
and randomized controlled trials from all settings
• Participants: Studies that evaluated the index tests for pulmonary TB in HIV-
positive and HIV-negative children aged 0 to 14 years with presumptive TB
• Index Test: Xpert MTB/RIF and Xpert Ultra
• Specimens: sputum, gastric aspirate, stool or nasopharyngeal specimens 
• Target Condition: Pulmonary TB
METHODS: REFERENCE STANDARDS
• Microbiologic Reference Standard: A positive culture on liquid or solid 
media from the same specimen type as the index test 
• The reference test for stool was a positive culture or Xpert test on a 
respiratory specimen
• Composite Reference Standard: A positive culture or a clinical decision to 
treat for TB based on clinical features
• If treatment decisions could not be abstracted then study specific 
definitions were used
METHODS: ANALYSIS
• Methodological quality assessed by QUADAS-2: patient selection, index 
test, reference standard, and flow & timing domains
• Performed meta-analyses using bivariate random-effects models when data 
were sufficient to estimate pooled results
• Investigated sources of heterogeneity by subgroup analysis: age groups, 
smear status, HIV status
• Sensitivity analyses were based on methodological quality
RESULTS
• 49 studies, which provided 299 data sets (68,544 participants) for 
pulmonary TB
• 80% of studies were performed in TB high-burden settings
•Median TB prevalence in the included studies was similar across 
specimen types ranging from 7-11%
RESULTS: SPUTUM
Xpert MTB/RIF against Culture (23 studies, 6612 participants)
• Sensitivity: 64.6% (95% CI 55.3 to 72.9) 
• Specificity: 99.0% (95% CI 98.1 to 99.5)
Xpert MTB/RIF against Composite (16 studies, 4379 participants)
• Sensitivity: 19.7% (95% CI 12.1 to 30.4) 
• Specificity: 100% (95% CI 100 to 100) 
Xpert Ultra against Culture (3 studies, 697 participants)
• Sensitivity: 72.8%(95% CI 64.7 to 79.6)
• Specificity: 97.5% (95% CI 95.8 to 98.5) 
Xpert Ultra against Composite (3 studies, 753 participants)
• Sensitivity: 23.5% (95% CI 20.0 to 27.4) 
• Specificity: 99.2% (95% CI 96.9 to 99.8) 
RESULTS: GASTRIC ASPIRATION
Xpert MTB/RIF against Culture 
(14 studies, 3482 participants):
• Sensitivity: 73.0% (95% CI 52.9 to 86.7) 
• Specificity: 98.1% (95% CI 95.5 to 99.2) 
Xpert MTB/RIF against Composite 
(6 studies, 933 participants): 
• Sensitivity: 31.7% (95% CI 20.2 to 46.0) 
• Specificity: 99.7% (95% CI 97.1 to 100) 
* No studies evaluated Xpert Ultra on gastric aspiration
RESULTS: NASOPHARYNGEAL ASPIRATION
Xpert MTB/RIF against Culture 
(4 studies, 1125 participants): 
• Sensitivity 45.7% (95% CI 27.6% to 65.1%) 
• Specificity: (4 studies, 981 participants): 
99.6% (95% CI 98.9 to 99.8) 
Xpert Ultra against Culture 
(1 study, 195 participants): 
• Sensitivity 45.7% (95% CI 28.9 to 63.3)
• Specificity 97.5% (95% CI 93.7 to 99.3) 
*Composite reference standard was not assessed 
due to limited data
RESULTS: STOOL
Xpert MTB/RIF against Culture (11 studies, 
1512 participants):
• Sensitivity: 61.5% (95% CI 44.1 to 76.4)
• Specificity: 98.5% (95% CI 97.0 to 99.2)
Xpert MTB/RIF against Composite (10 
studies, 1739 participants): 
• Sensitivity: 16.3% (95% CI 8.4 to 29.2)
• Specificity: 99.7% (95% CI 97.8 to 100) 
*No studies evaluated Xpert Ultra on stool
RESULTS: RIFAMPICIN RESISTANCE
• Xpert MTB/RIF pooled sensitivity against culture or LPA DST was: 
90.0% (95% CI 67.6% to 97.5%) and specificity was 98.3% (95% CI 
87.7% to 99.8%) 
*No studies evaluated Xpert Ultra rifampicin resistance detection
CONCLUSIONS
• Xpert MTB/RIF sensitivity varied by specimen type but 95% CIs overlapped
• Gastric aspirate specimens had the highest sensitivity followed by sputum and stool, 
and nasopharyngeal specimens the lowest; specificity in all specimens was > 98%
• Compared with Xpert MTB/RIF, Xpert Ultra sensitivity in sputum was higher (overlapping 
95% CIs) and specificity was slightly lower
• The small number of studies and reliance on stored specimens limits our confidence in 
the precision of the accuracy estimates for Xpert Ultra
• Test sensitivity remains poor against a composite reference standard. Treatment 
decisions should be based on the entirety of clinical information and treatment not 
withheld based solely on an Xpert MTB/RIF or Xpert Ultra result. 
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